NCT01669512View on ClinicalTrials.gov

Adjuvanting Viral Vectored Malaria Vaccines With Matrix M

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
MalariaMatrix M
Interventions
BIOLOGICAL

Control Regimen

ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56

BIOLOGICAL

Low Dose Matrix M Regimen

ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56

BIOLOGICAL

Standard Dose Matrix M Regimen

ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01669512 - Adjuvanting Viral Vectored Malaria Vaccines With Matrix M | Biotech Hunter | Biotech Hunter